ProCE Banner Activity

TRIPLETE: Phase III Trial of First-line mFOLFOXIRI + Panitumumab vs mFOLFOX6 + Panitumumab in RAS/BRAF Wild-Type mCRC

Slideset Download
Conference Coverage
Intensification of first-line chemotherapy with mFOLFOXIRI in combination with panitumumab did not improve response rate, depth of response, or PFS in patients with RAS and BRAF wild-type mCRC.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab